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Abstract 
Nicotine (NIC), the main psychostimulant compound of smoked tobacco, exerts 
its effects through activation of central nicotinic acetylcholine receptors 
(nAChR), which become up-regulated after chronic administration. Recent work 
has demonstrated that the recreational drug 3,4-methylenedioxy-
methamphetamine (MDMA) has affinity for nAChR and also induces up-
regulation of nAChR in PC 12 cells. Tobacco and MDMA are often consumed 
together. In the present work we studied the in vivo effect of a classic chronic 
dosing schedule of MDMA in rats, alone or combined with a chronic schedule of 
NIC, on the density of nAChR and on serotonin reuptake transporters. MDMA 
induced significant decreases in [3H]paroxetine binding in the cortex and 
hippocampus measured 24 h after the last dose and these decreases were not 
modified by the association with NIC. In the prefrontal cortex, NIC and MDMA 
each induced significant increases in [3H]epibatidine binding (29.5 and 34.6%, 
respectively) with respect to saline-treated rats, and these increases were 
significantly potentiated (up to 72.1%) when the two drugs were associated. 
Also in this area, [3H]methyllycaconitine binding was increased a 42.1% with 
NIC+MDMA but not when they were given alone. In the hippocampus, MDMA 
potentiated the α7 regulatory effects of NIC (raising a 25.5% increase to 52.5%) 
but alone was devoid of effect. MDMA had no effect on heteromeric nAChR in 
striatum and a coronal section of the midbrain containing superior colliculli, 
geniculate nuclei, substantia nigra and ventral tegmental area. Specific 
immunoprecipitation of solubilised receptors suggests that the up-regulated 
heteromeric nAChRs contain α4 and β2 subunits. Western blots with specific α4 
and α7 antibodies showed no significant differences between the groups, 
indicating that, as reported for nicotine, up-regulation caused by MDMA is due 
to post-translational events rather than increased receptor synthesis. 
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1. Introduction 
 
3,4-Methylenedioxy-methamphetamine (MDMA, ecstasy) is an amphetamine 
derivative used illicitly in developed countries for recreational purposes, usually 
by young people in night clubs and at extended dance parties (known as raves).  
 
A number of fatalities have been reported after acute consumption of this drug 
but there also exists experimental evidence that chronic MDMA can induce 
serotonergic and, to a lesser extent, dopaminergic neurotoxicity in rats and 
primates (see Capela et al. (2009) for a review). Also, serotonergic (Erritzoe et 
al., 2011; Reneman et al., 2002) and cognitive (Adamaszek et al., 2010; Nulsen 
et al., 2010; Parrott et al., 1998; Quednow et al., 2006) deficits have been 
reported in human chronic MDMA users, which could be due to neurotoxicity or 
to drug-induced long-lasting regulatory changes (Biezonski and Meyer., 2011). 
 
The neurotoxicity of amphetamine derivatives can be a consequence of 
coordinated oxidative stress, metabolic compromise and inflammation (see 
Capela et al., 2009 and Yamamoto and Raudensky, 2008 as reviews), and we 
have recently reported that neuronal acetylcholine nicotinic receptors (nAChR), 
mainly the homomeric α7 subtype, also play a key role in MDMA-induced 
neurotoxicity as the blockade of these receptors by the antagonists 
methyllycaconitine (MLA) or memantine prevents in vitro and in vivo MDMA-
induced neurotoxicity (Chipana et al., 2006, 2008a, 2008b, 2008c) as well as 
cognitive impairment in rats (Camarasa et al., 2008). Also, using radioligand 
binding experiments, we have demonstrated that MDMA has affinity for both 
homomeric and heteromeric nAChRs and behaves as a partial agonist at α7 
nAChR (Chipana et al., 2008b, 2008c; Garcia-Rates et al., 2007, 2010).  
 
NAChR are a family of ligand-gated cation channels widely distributed in the 
brain and the peripheral nervous system, whose subunit composition and 
signalling effects depend on subtype and localisation (Albuquerque et al., 2009; 
Gotti et al., 2007). They exert a number of effects on brain functions, involving 
fast synaptic transmission, cognitive enhancement, memory or reinforcement, 
and they are the main target of smoked nicotine. In the brain, nAChRs are 
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pentameric structures formed by the association of  and  subunits and can be 
either homomeric or heteromeric. The homomeric family is made up of the α7- 
α10 subunits and is sensitive to α-bungarotoxin (αBgTx), while the heteromeric 
receptors consist of combinations of α2- α6 and β2-β4 subunits, and are 
insensitive to αBgTx. Of these combinations, the most abundant are homomeric 
α7 and heteromeric (α4)2(β2)3 receptors. A particular feature of some nAChR 
subtypes is that, after chronic nicotine exposure, they undergo radioligand 
binding up-regulation, changes in stoichiometry and increase in their functional 
state (functional up-regulation) (reviewed by Gaimarri et al., 2007). Such up-
regulation occurs at a post-translational level and several mechanisms have 
been proposed to explain it, including a chaperone-like maturation enhancing 
effect of nicotine (Lester et al., 2009; Kuryatov et al., 2005; Sallette et al., 2005; 
Srinivasan et al., 2011;) and stabilisation of the high-affinity state of the 
receptors (Vallejo et al., 2005). Moreover, nAChR play a key role in addiction to 
nicotine (Govind et al., 2009), so up-regulation could enhance addiction to 
nicotine by increasing the pleasant effects of the drug. 
 
In a previous study on PC12 cells, we demonstrated that MDMA pretreatment 
induces in vitro up-regulation of both homomeric and heteromeric receptors 
(Garcia-Rates et al., 2007) through a mechanism that seemed to mimic that of 
nicotine. Then it was of interest to assess whether MDMA induces nAChR up-
regulation in vivo as well, as changes in these receptors could have a role in 
drug addiction and explain some psychiatric effects of this drug, such as 
memory impairment and psychoses, among others in which nAChRs have been 
found to play a role (Levin et al., 2002; Martin et al., 2004; Ripoll et al., 2004). 
  
Consequently, the aim of this study was to determine whether treatment with 
MDMA induces in vivo nAChR up-regulation and, moreover, to investigate 
whether it affects or potentiates the up-regulatory effects of nicotine, as MDMA 
and tobacco are very often associated (Scholey et al., 2004) and this could 
have implications on the addiction induced by both drugs.  
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2. Material and Methods 
 
2.1 Drugs and radioligands 
 
MDMA hydrochloride, obtained from the National Health Laboratory (Barcelona, 
Spain), was dissolved in saline (0.9% NaCl). Nicotine bitartrate dihydrate, 
purchased from Sigma-Aldrich (St. Louis, MO, USA), was also dissolved in 
saline. [3H]MLA came from American Radiolabeled Chemicals (St. Louis, MO, 
USA), while [3H]paroxetine, and [3H]epibatidine came from Perkin-Elmer 
(Boston, MA, USA). All buffer reagents were of analytical grade and purchased 
from several commercial sources. 
 
2.2 Animals and treatment 
 
The experimental protocols for the use of animals in this study follow the 
guidelines set out by the European Communities Council (86/609/EEC) and 
were supervised by the ethics committee of the University of Barcelona. Male 
Sprague-Dawley rats weighing 200-230 g (Harlan Ibérica, Barcelona, Spain) 
were used. They were housed at 21ºC ± 1ºC under a 12 h light/dark cycle with 
free access to food and drinking water.  
 
At the beginning of the treatment they were housed one per cage and a 
combined nicotine and MDMA dosing schedule was carried out for 10 days as 
follows. Six animals were used in each treatment group. The control (Ctrl) group 
received saline (1 ml/kg s.c.) twice daily (7-h interval) for the 10 days; the 
nicotine (NIC) group received 2 mg/kg nicotine bitartrate dihydrate (s.c.) twice 
daily (7-h interval) for 10 days (Flores et al., 1992); the MDMA group was given 
saline (s.c.) twice a day from days 1 to 6, and 20 mg/kg MDMA (s.c., b.i.d., 7-h 
interval) from days 7 to 10 (Battaglia et al., 1987). The MDMA+NIC group 
received nicotine bitartrate for the 10 days as stated for the NIC group, and 
MDMA (same dosing as above) was also injected during the last 4 days, 15 
min. after nicotine and at a different puncture site. The rats were weighed at 
days 1, 4, 6 and 11 and the percentage increase calculated throughout the 
treatment. 
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The rats were killed by decapitation under isoflurane anaesthesia on day 11. 
The brains were rapidly removed from the skull and dissected on a refrigerated 
surface. Prefrontal and parietal cortex, striatum, hippocampus, and a coronal 
block delimited by the thickness of superior colliculi, after removal of cortex and 
hippocampus (contains the colliculi, the geniculate nuclei, the substantia nigra 
and the ventral tegmental area, VTA), were excised, frozen on dry ice and 
stored at -80ºC until use. 
 
These areas were selected on the basis of their abundance in the different 
types of nAChR, ease to be dissected and the amount of protein to perform 
binding assays in homogenates. Thus heteromeric nAChR were measured in 
cortex, striatum and the section containing the colliculi, as they express high 
levels of these receptors. As for α7 nAChR, they were assessed in the 
hippocampus (where they are more abundant and there are low levels of α4β2) 
and in the cortex as well (Tribollet et al., 2004). 
 
2.3 Tissue processing 
 
When required, tissue samples were thawed and homogenised at 4ºC in 10 
volumes of buffer consisting of 5 mM Tris-HCl, 320 mM sucrose, and protease 
inhibitors (aprotinin 4.5 µg/µl, 0.1 mM phenylmethylsulfonyl fluoride, and 1 mM 
sodium orthovanadate), pH 7.4, with a Polytron homogeniser. The 
homogenates were centrifuged at 15,000 x g for 30 min at 4ºC. The resulting 
pellets were resuspended in fresh buffer, incubated 5 min at 37ºC to degrade 
remaining endogenous ligands and recentrifuged twice. The final pellets of 
membrane homogenates were resuspended in 50 mM Tris-HCl buffer (plus 
protease inhibitors) and stored at -80ºC until use in radioligand binding assays 
or receptor solubilisation for Western blotting or immunoprecipitation. Protein 
content was determined using the Bio-Rad Protein Reagent (Bio-Rad Labs., 
Inc., Hercules, CA, USA), according to the manufacturer’s instructions. 
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2.4 [3H]Paroxetine binding 
 
The density of serotonin transporters (SERT) in each rat’s cortex and 
hippocampus was determined to assess the serotonergic changes/neurotoxicity 
induced by MDMA (Pubill et al., 2003). This was accomplished by measuring 
the specific binding of 0.05 nM [3H]paroxetine after incubation with 150 µg 
protein at 25ºC for 2 h in a Tris-HCl buffer (50 mM, pH 7.4), containing 120 mM 
NaCl and 5 mM KCl to a final volume of 1.6 ml. Clomipramine (100 µM) was 
used to determine non-specific binding.  
 
2.5 [3H]MLA binding  
 
Binding of 2 nM [3H]MLA to label α7 nAChRs was performed in duplicates for 
each rat and brain area as described by Davies et al.(1999). Membrane 
homogenates (250 μl containing 200 μg protein) were incubated with the 
radioligand in glass tubes in a final volume of 0.5 ml for 2 h at 4ºC. Incubation 
buffer consisted of 50 mM Tris–HCl, 120 mM NaCl, 2 mM CaCl2, 1 mM MgSO4 
and 0.1% bovine serum albumin. Non-specific binding of each animal/area was 
determined from tubes containing 1 μM unlabelled MLA to be subtracted from 
total binding values. Incubation was terminated by rapid filtration and bound 
radioactivity counted as described below. 
 
2.6 [3H]Epibatidine binding  
 
[3H]Epibatidine binding was used to label heteromeric nAChRs. Binding was 
measured for each rat and brain area in glass tubes containing 1 nM 
[3H]epibatidine and 200 μg of membrane homogenates in buffer (50 mM Tris-
HCl plus protease inhibitors) to a final volume of 0.5 ml. Incubation was carried 
out for 2 h at 25ºC. Non-specific binding was determined in the presence of 300 
μM nicotine. Binding was terminated by filtration and data were treated as 
described below. 
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2.7 Bound radioligand separation and counting 
 
For all radioligand binding experiments, incubation was finished by rapid 
filtration under vacuum through GF-B glass fibre filters (Whatman, Maidstone, 
UK) pre-soaked in 0.5% polyethyleneimine. Tubes and filters were rapidly 
washed four times with 4 ml of ice-cold buffer, and the radioactivity trapped was 
measured by liquid scintillation spectrometry. Specific binding was calculated as 
the difference between the radioactivities measured in the absence (total 
binding) and in the presence (non-specific binding) of the excess of non-labelled 
ligand. 
 
2.8 Receptor solubilisation and radioimmunoprecipitation 
 
Aliquots of tissue homogenates were centrifuged at 15,000 x g for 30 min at 
4ºC. The supernatants were discarded and the pellets were resuspended in an 
appropriate volume of ice-cold solubilisation buffer consisting of 20 mM Tris HCl 
pH 8, 137 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, 4.5 µg/µl aprotinin and 0.1 
mM phenylmethylsulfonyl fluoride. The receptors were solubilised by incubation 
for 2 h at 4ºC under gentle rotation. Thereafter, the samples were centrifuged at 
15,000 x g for 30 min at 4ºC and the supernatants containing solubilised 
receptors were stored at -80ºC after determination of protein content using the 
Bio-Rad Protein Reagent and bovine serum albumin standards prepared in the 
same dilution of solubilisation buffer, in order to compensate for the reaction 
with the buffer detergent. 
 
Immunoprecipitation of receptors containing 4 and 2 subunits was performed 
as described by Turner and Kellar (2005) with some modifications. Rabbit 
polyclonal antibody anti-nAChR 4 subunit was purchased from Abcam 
(Cambridge, UK) and rat monoclonal anti-nAChR 2 subunit, clone mAb290 
was obtained from Sigma-Aldrich (St. Louis, MO, USA). Aliquots of solubilised 
receptors containing 300 μg protein were added to sample tubes containing 1.5 
nM [3H]epibatidine and 1 µg of either one of the subunit-specific antibodies or 
the same volume of normal rabbit serum (supplied by the animal facilities 
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service of the Faculty of Pharmacy, University of Barcelona) in the case of 4 or 
rat normal IgG (Invitrogen Corp., Carlsbad, CA, USA) in the case of 2, in order 
to determine non-specific immunoprecipitation. The optimal antibody 
concentration (1 µg) was obtained from pilot experiments, and 1.5 nM 
[3H]epibatidine was chosen to ensure the occupation of nearly all the 
heteromeric receptors. The final volume of each test tube was 180 µl. The 
samples were incubated overnight at 4ºC under gentle rotation and then 25 µl of 
a slurry of either Protein A-agarose or Protein G Plus-Agarose (Santa Cruz 
Biotechnology, Inc.) was added to each tube for 4 or 2 antibody precipitation, 
respectively. The rotation of the samples was continued for an additional hour. 
The samples were then centrifuged at 7,000 x g for 5 min. and the supernatants 
carefully removed. The pellets were washed with 0.75 ml of cold 50 mM Tris-
HCl buffer pH 7.4 and recentrifuged. The supernatants were discarded and the 
immunoprecipitate pellets were dissolved in 100 µl of 1 N NaOH, transferred to 
scintillation vials and the radioactivity counted in a liquid scintillation counter 
after addition of liquid scintillation fluid (Ultima Gold MV, Perkin Elmer, Boston, 
MA, USA). The counts precipitated in tubes containing normal rabbit serum or 
rat IgG, which were used as control for non-specific precipitation, were 
subtracted from the counts obtained in the presence of the specific antibody, in 
order to calculate specific immunoprecipitation. 
 
Total epibatidine binding was measured in parallel samples, incubated under 
the same conditions but without antibody and agarose beads. After overnight 
incubation they were filtered through Whatman GF-B glass fibre filters that had 
been pre-wet with 0.5% polyethyleneimine, using a cell harvester (Perkin Elmer 
filter mate), followed by four 1 ml washes. The radioactivity trapped on the filters 
was measured by liquid scintillation spectrometry as above. Non-specific 
binding was determined from tubes containing 300 µM nicotine. 
 
2.9 Western blotting and immunodetection 
 
A general Western blotting and immunodetection protocol was used to 
determine 4 and 7 subunit levels in the protein extracts. For each sample, 40 
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μg of protein was mixed with sample buffer (62.5 mM Tris-HCl, pH 6.8, 10% 
glycerol, 2% (w/v) SDS, 5% (v/v) 2-β-mercaptoethanol, 0.05% bromophenol 
blue, final concentrations), boiled for 10 min, and loaded onto a 10% 
polyacrylamide gel. Proteins were separated by electrophoresis until the elution 
of the migration front and transferred from gels to polyvinylidene fluoride sheets 
(Immobilon-P; Millipore, Billerica, MA, USA). These sheets were then blocked 
for 1 h at room temperature with 5% defatted milk in Tris-buffered saline buffer 
plus 0.05% Tween 20 (TBS-T buffer) and incubated overnight at 4ºC with either 
rabbit polyclonal antibody against α7 subunit (ab23832) or rabbit polyclonal 
anti-α4 subunit (ab41172), both purchased from Abcam (Cambridge, UK) and 
used at a 1:1000 dilution in TBS-T buffer plus 5% defatted milk. Thereafter, 
membranes were washed with TBS-T buffer and incubated for 45 min with 
peroxidase-conjugated secondary antibody (donkey anti-rabbit IgG, 1:20,000 
dilution; GE Healthcare, Buckinghamshire, UK,).  
 
Immunoreactive protein was visualised using a chemoluminescence-based 
detection kit following the manufacturer’s protocol (Immobilon Western, 
Millipore, Billerica, MA, USA) and a BioRad ChemiDoc XRS gel documentation 
system (BioRad Labs., Hercules, CA, USA). Apparent molecular weight bands 
corresponding to the target proteins were 56 kDa for α7 subunit and 70 kDa for 
α4 subunit. Scanned blots were analysed using BioRad Quantity One software. 
Immunodetection of -actin (mouse monoclonal anti -actin antibody, Sigma, 
St. Louis, USA; dil.1:2500) served as a control of load uniformity for each lane 
and was used to normalise differences due to protein content. The -actin band 
appeared at a molecular weight of approximately 42 kDa. The α7 and α4 levels 
are expressed as a percentage of those obtained from saline-treated animals.  
 
2.10 Statistical Analysis 
 
All data are expressed as mean ± standard error of the mean (S.E.M.) of the 
values obtained for each treatment group. Two-way analysis of variance 
(ANOVA) for repeated measures was used to analyse the effect of the 
treatment in the temporal evolution of body weight gain. The rest of statistical 
comparisons were made using one-way ANOVA (two-tailed). Significant 
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(P<0.05) differences were then analysed by Tukey’s post-hoc test for multiple 
means comparisons, where appropriate. All statistic calculations were 
performed using PASW Statistics v-18 (SPSS software, IBM, New York, USA).  
 
3. Results 
 
3.1 Effect of treatment on body weight gain 
 
Figure 1 depicts the evolution of body weight in the different treatment groups. 
As can be seen, the main differences among the groups start at the point that 
MDMA was introduced. The two-way ANOVA analysis for repeated measures 
reported significant differences in the effects of the treatment  (F3,21= 5.77, 
P<0.01) and during the days of treatment (F3,21= 18.93, P<0.001).  At day 11, 
the MDMA group significantly had gained less weight than saline (P<0.01) and 
the MDMA+NIC group had gained even less weight than the MDMA group 
(P<0.001 vs. saline), although differences between these two groups did not 
reach statistical significance. No significant differences were found between 
NIC- and saline-treated animals.  
 
3.2 Effects of treatment on serotonin transporter density 
 
Binding of [3H]paroxetine was performed in the parietal cortex and hippocampus 
in order to assess the possible deleterious effect of drug treatment on 
serotonergic terminals. Results are presented in table 1. In the cortex, a 
significant decrease (around 70%) in [3H]paroxetine binding was found in 
MDMA-treated animals (P<0.001 vs. saline), while NIC did not modify these 
levels. In the hippocampus, the decrease in binding was more modest (around 
20%) and it was not modified by nicotine either. 
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Table 1 
Binding of [3H]paroxetine to membranes from parietal cortex (pCTX) and 
hippocampus of rats treated with saline (control), MDMA, NIC or the 
combination of NIC+MDMA, as stated in 2. Results are expressed as the 
percentage of the specific binding obtained in control rats and they are the 
mean ± S.E.M. of the values obtained from 5-6 animals per group. 
 
 Control MDMA NIC NIC + MDMA 
pCTX 100.0 ± 3.6 33.7 ± 3.1 ***     91.0 ± 4.1 26.94 ± 13.7 *** 
HC 100.0 ± 2.9 83.9 ± 5.5 * 114.0 ± 7.2 77.1 ± 5.6 ** 
 
* P<0.05; ** P<0.01; *** P<0.001 vs. control group. One-way ANOVA and Tukey’s post-hoc test. 
 
    
3.3 Effects on [3H]epibatidine binding 
 
The levels of heteromeric nAChRs were measured through [3H]epibatidine 
binding assays and are shown in Fig. 2. In the parietal cortex, NIC and MDMA 
separately induced significant increases in binding of 18.0 ± 3.6% and 16.5 ± 
5.8% respectively, compared with saline-treated rats. When NIC and MDMA 
were associated, such effects were significantly potentiated, rising to a 29.1 ± 
5.7% increase. Similar but more pronounced effects were found in the frontal 
cortex , where NIC and MDMA separately induced increases of 29.5 ± 10.7% 
and 34.6 ± 9.2%, respectively, that rose to 72.1 ± 17.5% when both drugs were 
associated. By contrast, in the striatum and in the coronal section delimited by 
the superior colliculi, NIC alone induced an increase in binding of 41.3 ± 5.5% 
and 47.4 ± 15.4%, respectively, but not MDMA, which did not modify NIC-
induced up-regulation. In the cerebellum, no significant increases were found in 
any of the treatment groups (data not shown). 
 
3.4 Effects on [3H]MLA binding 
 
The levels of homomeric nAChRs (mainly 7) were measured using [3H]MLA 
binding. The results are shown in Fig. 3. In the prefrontal cortex, MDMA and 
NIC failed to induce significant up-regulation separately, but the association of 
the two drugs led to a significant increase of 42.1 ± 20% in [3H]MLA binding. In 
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the parietal cortex, MDMA induced a slight up-regulation (15.3 ± 5.2% increase) 
that was not modified by its association with NIC, which alone did not induce 
any significant effect. 
 
By contrast, in the hippocampus (Fig. 3C), MDMA alone did not induce any 
change in [3H]MLA binding but potentiated the regulatory effects of NIC, which 
rose from a 25.5 ± 7.6% to a 52.5 ± 11.3% increase when both drugs were 
associated. 
 
In the striatum, none of the treatments induced significant changes in [3H]MLA 
binding (data not shown). 
 
3.5 4 and 7 subunit expression 
 
Western blot analysis using specific antibodies against 4 and 7 nAChR 
subunits was performed in the areas where the most marked increases had 
been found, that is, in the prefrontal cortex for 4 and the hippocampus for 7. 
No significant changes in protein expression were observed among the different 
treatment groups (Fig. 4). 
 
3.6 4 and 2 subunit immunoprecipitation 
 
To assess which subunits of heteromeric receptors were up-regulated, we 
performed immunoprecipitation of 4 and 2-containing receptors labelled with 
[3H]epibatidine using prefrontal cortex extracts, where the most marked effects 
on radioligand binding were found. The results are shown in Fig. 5. Overall, the 
increases in binding in the different treatment groups paralleled those observed 
in binding to membranes. The potentiation of the up-regulation was only seen in 
the α4 immunoprecipitate. Immunoprecipitation with anti-2 antibody trapped 
100% of specifically-bound radioligand, indicating that in this area, all receptors 
labelled with [3H]epibatidine contained this subunit. Immunoprecipitation with 
anti-α4 trapped around 80% of total binding. 
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4. Discussion 
 
Nicotinic receptors play a key role in addiction to nicotine (Govind et al., 2009). 
It has been described that the addictive effects of nicotine are produced through 
its interaction with nAChR in the mesolimbic pathway, especially those in the 
nucleus accumbens, leading to dopamine release that activates the reward 
circuitry. In fact, mice with deletion of the β2 gene do not self-administer 
nicotine after previous administration and do not show increased release of 
dopamine in the ventral tegmental area (Picciotto et al., 1999). Although the 
mechanisms involved in the establishment of addiction are complex and still 
being investigated, up-regulation of nAChR increasing the pleasant effects of 
the drug is an event that could feasibly play a role. It is thought that up-
regulation of nAChR is a homeostatic response to the rapid desensitisation of 
the receptors induced after prolonged exposure to an agonist (Fenster et al., 
1999) in order to re-establish the nicotinic pathways. Several mechanisms have 
been proposed to explain such up-regulation and they are mentioned and cited 
in the Introduction section. 
 
According to our previous study (Garcia-Rates et al., 2007, 2010) 
demonstrating that MDMA had affinity for and induced nAChR up-regulation in 
PC12 cells, it was of interest to assess whether the regulatory effects of MDMA 
on nAChR could take place in vivo after repeated administration of MDMA as 
well. Also, because MDMA and nicotine (smoked tobacco) are often associated 
(Scholey et al., 2004), we tested the effect of such an association on nAChR 
up-regulation. One important issue was the selection of the dosing schedule. 
Studies involving nicotine have used either a repeated dosing schedule or the 
implantation of sustained-release osmotic minipumps (Even et al., 2008; 
Nguyen et al., 2003) or constant infusion (Marks et al., 2011; Pauly et al., 1996) 
to achieve constant plasmatic levels, thus reaching the highest levels of nAChR 
up-regulation. The use of these drug delivery methods was rejected for MDMA 
because of possible organ failure after prolonged and sustained plasmatic 
levels and because this drug is not consumed as continuously as nicotine. For 
this reason we chose the established MDMA chronic dosing schedule (20 
mg/kg b.i.d. for 4 days) and combined it with one of the schedules reported in 
 15
the literature for nicotine, involving two injections per day for 10 days (Flores et 
al., 1992). The relatively high dose of MDMA was chosen based on the fact 
that, according to radioligand binding experiments (Garcia-Rates et al., 2007), 
low micromolar concentrations had to be reached in the target area and 
mantained enough time to induce the up-regulation and also because this is a 
generally accepted schedule of chronic MDMA (Battaglia et al., 1987). 
 
An inconvenience of such a dosing schedule is the possibility of serotonergic 
neurotoxicity from MDMA. MDMA-induced hyperthermia can potentiate its 
neurotoxic events, although it is not mandatory for the long–term neurotoxicity 
that follows MDMA administration (Capela et al., 2009). For this reason, the 
treatment was carried out at 20ºC-21ºC in order not to exacerbate the 
neurotoxic effects by facilitating the hyperthermia (Gordon et al., 1991; Green et 
al., 2005). At ambient temperatures between 20ºC-24ºC, no changes in 
serotonin and 5-hydroxyindolacetic acid were reported following MDMA 
administration (Malberg et al., 1998), although decreases in [3H]paroxetine have 
been reported at these temperatures (O’Shea et al., 2006). In fact the changes 
in [3H]paroxetine binding have been claimed to be a more reliable marker of 
MDMA-induced neurotoxicity, rather than the loss of serotonin and its 
metabolites (O’Shea et al., 2006). However, we must point out that in our 
treatment the rats were killed 24 h after the last dose, while most studies (i.e. 
(Biezonski and Meyer, 2010; Broening et al., 1995; Malberg et al., 1998; 
O’Shea et al., 1998; O’Shea et al., 2006; Pubill et al., 2003) make the 
measurement after leaving a time of at least one week to allow the neurotoxic 
process to occur. Interestingly, we found a robust decrease (around 70%) in 
[3H]paroxetine binding in cortex from MDMA-treated rats as early as 24 h after 
the last dose, a time at which the development of axonal and terminal 
degeneration is unlikely. Also we must point out that measuring [3H]paroxetine 
binding at only one radioligand concentration (0.05 nM) does not inform us on 
whether the observed decrease is due to a drop in total number of transporters 
(Bmax) or to a decrease in the affinity (increase in KD). Battaglia et al. (1987) 
used the same MDMA schedule than us but measured binding two weeks after 
treatment. They performed saturation binding assays and demonstrated that the 
 16
reduction in [3H]paroxetine binding after MDMA treatment was due to a 
decrease in Bmax without significant changes in KD.  
 
Recent studies, however, have raised the question whether serotonergic marker 
depletion caused by MDMA is reflective of neurodegeneration or rather is an 
effect of biochemical down-regulation in the absence of tissue damage 
(Biezonski and Meyer, 2011). In fact, a significant reduction in SERT gene 
expression, which could explain a reduction in SERT protein irrespective of 
altered terminal integrity, has been reported after treatment with MDMA 
(Biezonski and Meyer, 2010). Both terminal destruction and SERT down-
regulation would produce reductions in Bmax. On the other hand, a decrease in 
KD could be caused by the presence of MDMA in the binding medium (which is 
unlikely in our case seeing as the preparation is washed several times before 
binding) or by acute modifications (i.e. phosphorilation, nitrosilation) in the 
transporter as has been documented for the dopamine transporter (Hansen et 
al., 2002). In fact, in a previous study from our group (Escubedo et al., 2011), 
we demonstrated that incubation of rat brain synaptosomes with MDMA for 1 h 
induced a decrease in [3H]5-HT uptake measured after drug removal, which 
indicates that a rapid change in SERT leading to an impaired function was 
produced. This change could also involve a decreased affinity for paroxetine. 
Due to the fact that our rats were killed 24 h after treatment, such an effect 
decreasing affinity for the radioligand cannot be definitely ruled out. 
 
Regardless of the fact that neurotoxicity could develop after this treatment, it 
can be assumed that changes in nAChR density after moderate-high doses of 
MDMA take place before the neurodegenerative process begins. 
 
The temporal evolution of rats’ body weight was studied to ascertain an easily 
measurable effect of MDMA and to study any possible interaction with nicotine. 
The rats treated with MDMA gained less weight than controls due to the 
anorectic effect of the drug. Serotonin (5-HT) 5-HT4 receptors in the nucleus 
accumbens are specifically involved in the appetite-suppressant effects of this 
drug inducing 5-HT release (Francis et al., 2011). Although nicotine had no 
significant effects on body weight gain, the graph of the association with MDMA 
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suggests a tendence, although not statistically significant, of impaired weight 
gain in this treatment group. It is known that nicotine relieves anxiety and 
people who give up smoking increase food intake (Schnoll et al., 2012). In this 
context, nicotine could enhance the lack of appetite induced by MDMA leading 
to less weight gain although, as mentioned, this did not reach statistic 
significance. 
 
After this treatment, MDMA induced up-regulation of heteromeric and α7 
nAChR in several rat brain areas. Moreover, a synergistic effect was observed 
in the cortex for heteromeric nAChR and in the hippocampus for the α7 type. 
Accordingly, these two areas contain a high density of serotonergic innervation 
in addition to nAChR, and are main targets of MDMA. In striatum and the 
section containing superior colliculi, lateral geniculate nuclei, substantia nigra 
and VTA, only the effect of NIC was detected. With the data to hand, any 
explanation for such a difference can only be a matter of speculation. Striatum, 
geniculate nuclei, substantia nigra and especially superior colliculi exhibit higher 
heteromeric nAchR density than cortex and hippocampus (Tribollet et al., 2004) 
and are highly sensitive to up-regulation by nicotine (Nguyen et al., 2003). It 
might be that MDMA-induced up-regulation in striatum and colliculi was so 
modest in these tissues with high receptor density that the increases do not 
reach statistical significance. In fact, an upward trend can be seen in the 
striatum in the MDMA group. 
 
The effect of NIC on α7 nAChR was less marked than that on heteromeric 
receptors. In fact, the affinity of NIC for α7 nAChR is in the micromolar range 
while the KD for heteromeric nAChR is nanomolar (Marks et al., 1986), so 
higher concentrations of NIC had to be achieved in a given brain area to induce 
such up-regulation. Also it must be pointed out that the intermittent NIC dosing 
schedule used could not be as potent at inducing α7 nAChR up-regulation as 
continuous administration would be. As far as MDMA is concerned, it has higher 
affinity for heteromeric than for α7 nAChR (Garcia-Ratés et al., 2007), thus a 
more marked effect on the heteromeric receptors was expected and confirmed 
by the experimental results. It has been reported that exposure to α7 nAChR 
partial agonists increases the expression of these receptors in rodents 
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(Werkheiser et al., 2011) and that MDMA acts as a α7 partial agonist in PC12 
cells (Garcia-Rates et al., 2010). This would account for its effect on the density 
of α7 nAChR in the parietal cortex and the synergy with NIC seen in the cortex 
and hippocampus. 
 
When solubilised receptors were immunodetected with Western blotting, no 
significant changes were observed in levels of protein density, in agreement 
with the general assertion that up-regulation of nAChR takes place at a post-
translational level (reviewed by Gaimarri et al., 2007), promoting the assembly 
of nAChR subunits and their migration from the endoplasmic reticulum (ER) to 
the plasma membrane. Since our extracts were obtained from whole-tissue 
homogenates, the antibodies raised to a specific nAchR subunit did not 
distinguish between assembled plasma membrane receptors and intracellular 
ER-associated subunits at different stages of maturation. Conversely, 
radioligands preferentially labelled assembled/mature receptors. These results 
suggest that MDMA acts on nAChR similarly to nicotine, possibly even exerting 
a synergistic effect. 
 
Nicotine mainly induces up-regulation of α4β2 nAChR, which are the most 
abundant in mammals’ CNS. As [3H]epibatidine labels nearly all heteromeric 
nAChR, we performed the immunoprecipitation of receptors containing α4 and 
β2 subunits and carried out radioligand binding, in order to ascertain the 
participation of these subunits in the up-regulation process. The binding of the 
total solubilised extract paralleled that performed in crude membranes, 
indicating that up-regulation levels persist after receptor solubilisation. Up-
regulation of α4- and β2-containing receptors was found separately in the 
immunoprecipitates, but the synergy of the nicotine + MDMA association was 
found only in the α4 immunoprecipitate. This indicates that, similarly to what 
happens with nicotine, α4β2 nAChR are the main subtype that is up-regulated 
after treatment with MDMA in vivo. However, other associations containing the 
β2 subunit would be resistant to up-regulation because in the β2 
immunoprecipitate the increased binding levels were more modest and there 
was no synergy in the nicotine + MDMA association. In fact, several studies 
have demonstrated that not all nAChR subtypes undergo up-regulation and not 
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all show it to the same extent and under the same experimental conditions. For 
example, the α4β2α5 combination is resistant to up-regulation (Mao et al., 
2008), the α6-containing nAChR only undergo up-regulation at high but 
transient nicotine concentrations, while α4β2 nAChR require a lower 
concentration but a more prolonged exposure (Walsh et al., 2008); finally, α3β2 
and α3β4 subtypes undergo much lower up-regulation than α4β2 (Nguyen et 
al., 2003). Also the access of each ligand to a certain brain area and the nAChR 
subtype predominant in it could modify the up-regulation process.  
 
Both nicotinic agonists and antagonists are able to induce nAChR up-regulation 
due to their affinity for the receptors or their immature forms (Peng et al., 1994; 
Gopalakrishnan et al., 1997). In fact, we have previously demonstrated that 
MDMA behaves as a partial agonist on α7 nAChR and as an antagonist on 
α4β2, inducing significant up-regulation of both receptor types in PC 12 cells at 
a concentration of 1 μM (Garcia-Ratés et al., 2007, 2010), which has been 
reported to be reached in vivo (Johnson et al., 2004).   
 
Due to the complexity of brain synapses and regulation, an additional unknown 
mechanism involved in nAChR up-regulation after MDMA cannot definitely be 
ruled out. However, the previously reported results using cultured PC 12 cells 
demonstrate that the simple interaction of MDMA with nAChR is sufficient to 
induce the up-regulation. 
 
All this evidence makes the study of MDMA’s effects on nAChR levels as 
complex as the studies carried out on nicotine for more than 20 years by many 
research groups. What is warranted is the use of autoradiography to produce a 
closer mapping of more defined brain areas that show up-regulation after 
treatment with MDMA. Also, another challenge to face is to find a different 
dosing schedule that uses lower and potentially less neurotoxic MDMA doses, 
while increasing the duration of treatment.  
 
In conclusion, this is the first study to date that demonstrates an in vivo up-
regulation of nAChR after treatment with MDMA, as well as a synergistic effect 
when MDMA is associated with nicotine. Given that these two drugs are often 
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associated, the development of neuroadaptive processes in which nAChR play 
a role could be enhanced. Were specific areas to be affected, such as the 
ventral tegmental area and nucleus accumbens, there could be an increase in 
addiction and drug vulnerability. The fact of having taken one of these drugs 
could later make the subject more prone to the addictive effects of the other. 
Also, as α7 nicotinic receptors are involved in MDMA-induced neurotoxicity 
(cited above), an enhanced risk of toxicity in certain brain areas (i.e. the 
hippocampus) leading to cognitive impairment could be feasible. 
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Figure captions 
 
Figure 1: Evolution of body weight gain throughout the drug treatment. Nicotine 
was started at day 1 and MDMA at day 7. Drug administration was finished at 
day 10 and the rats were killed at day 11. The values are the means ± SEM of 
the body weight of six animals per group. **P<0.01, *** P<0.001 vs. saline. 
 
Figure 2: Binding of [3H]epibatidine to heteromeric nAChR in membranes from 
prefrontal cortex (A), parietal cortex (B), striatum (C) and the coronal section 
containing superior colliculi and substantia nigra (D) of rats belonging to the 
different treatment groups. Data are means ± SEM from 6 animals per group. 
Control (Ctrl) animals received saline. *P<0.05, **P<0.01; ***P<0.001 vs. Ctrl.;  
#P<0.01 vs. NIC; $P<0.05 vs. MDMA. 
 
Figure 3: Binding of [3H]methyllycaconitine ([3H]MLA) to homomeric α7 nAChR 
in membranes from prefrontal cortex (A), parietal cortex (B) and hippocampus 
(C) of rats belonging to the different treatment groups. Data are means ± SEM 
from 6 animals per group. Control (Ctrl) animals received saline. *P<0.05, 
**P<0.01 vs. Ctrl., #P<0.05 vs. NIC. 
  
Figure 4: Western blot analysis of nAChR subunits α4 (panel A) and α7 (panel 
B) in extracts of prefrontal cortex and hippocampus, respectively, from rats 
belonging to the different treatment groups. Bar graphs show overall 
quantification of the blots (mean ± SEM), while a representative 
autoradiography of each determination is shown above. β-actin levels were 
used to ensure gel loading uniformity and to normalise the protein values. 
 
Figure 5: Levels of [3H]epibatidine binging after immunoprecipitation with anti-
α4 (panel A) and anti-β2 (panel B) specific antibodies in cortex extracts of rats 
from the different treatment groups. Also, total binding to these extracts was 
measured in parallel samples (panel C) in order to calculate the percentage of 
immunoprecipitated binding. Data are the means ± SEM of values from 5-6 rats 
per group.  *P<0.05, **P<0.01; ***P<0.001 vs. Ctrl.;  #P<0.05, ##P<0.01 vs. 
NIC. 
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